Search Results
10
Everything
Search Filters
Organization
Tarsus Pharmaceuticals, Inc
Tarsus to Participate in Upcoming Investor Conference
March 06, 2025 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global...
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements
February 25, 2025 07:00 ET
|
Tarsus Pharmaceuticals, Inc
Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data;...
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
February 20, 2025 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February...
Tarsus to Participate in Upcoming Investor Conferences
January 30, 2025 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in fireside chats at two upcoming investor...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
January 13, 2025 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for...
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
November 13, 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two...
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
November 13, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
November 06, 2024 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
November 05, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
October 17, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...